Tropomyosin-related kinase (trk) inhibitors
US12318392B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2023 |
| Grant date | Jun 3, 2025 |
| Priority date | — |
| Expiry date | Nov 21, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/6561
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.